To the full analysis
Buyback calculator for ANI Pharmaceuticals
ANI Pharmaceuticals stock: key metrics
ANIPANI Pharmaceuticals had an operating margin of 9.2% and a return on invested capital (ROIC) of 9% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 100.0% | 23.8% | 19.3% |
| 2007 | 100.0% | −1,760.3% | −1,538.3% |
| 2008 | 100.0% | −476.4% | −460.9% |
| 2009 | 100.0% | −3,054.4% | −3,777.9% |
| 2010 | 89.1% | −1,762.5% | −1,867.1% |
| 2011 | 88.5% | −11,703.0% | −11,859.7% |
| 2012 | −298.4% | −1,007.1% | −1,204.7% |
| 2013 | 66.8% | 3.0% | 1.0% |
| 2014 | 79.5% | 35.7% | 51.4% |
| 2015 | 83.4% | 42.8% | 20.1% |
| 2016 | 62.1% | 15.6% | 3.1% |
| 2017 | 55.3% | 16.0% | −0.6% |
| 2018 | 63.8% | 17.5% | 7.7% |
| 2019 | 69.4% | 7.9% | 3.0% |
| 2020 | 58.2% | −7.7% | −10.8% |
| 2021 | 53.5% | −18.4% | −19.7% |
| 2022 | 56.1% | −11.2% | −15.1% |
| 2023 | 62.7% | 9.6% | 3.9% |
| 2024 | 59.3% | 0.1% | −3.0% |
| 2025 | 51.0% | 9.2% | 8.9% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | 15.4% | 51.9% | 12.5% |
| 2007 | −25.5% | −28.7% | −24.3% |
| 2008 | −100.0% | −65.4% | −98.6% |
| 2009 | −100.0% | no data | −100.0% |
| 2010 | −100.0% | −98.1% | −100.0% |
| 2011 | −100.0% | −86.7% | −82.7% |
| 2012 | −98.4% | −40.1% | −71.5% |
| 2013 | 0.7% | 4.9% | 0.7% |
| 2014 | 20.6% | 36.0% | 10.9% |
| 2015 | 9.6% | 23.1% | 5.4% |
| 2016 | 2.3% | 5.3% | 1.2% |
| 2017 | −0.6% | 4.7% | −0.3% |
| 2018 | 7.9% | 8.0% | 3.6% |
| 2019 | 2.9% | 4.9% | 1.3% |
| 2020 | −11.5% | −3.6% | −4.9% |
| 2021 | −11.9% | −6.8% | −5.5% |
| 2022 | −14.1% | −5.0% | −6.3% |
| 2023 | 4.1% | 8.1% | 2.1% |
| 2024 | −4.3% | 0.1% | −1.4% |
| 2025 | 14.5% | 9.0% | 5.4% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 7 Nov 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.